Trials / Completed
CompletedNCT01332500
Treximet ™ Pharmacy Budget Impact Model Database Validation Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61,737 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this retrospective claims database study was to compare the change in migraine-related prescription (i.e. NSAIDs, Opioids, Ergots) utilization among migraine suffers following initiation of Treximet ™ (sumatriptan/naproxen) compared with subjects initiating treatment with other orally available triptans. The study was used to validate the migraine-related prescription utilization patterns predicted by the Treximet ™ Budget Impact Model. The SourceLx dataset from the family of Wolters Kluwer databases was used for this analysis. The database contains 30% of prescription claims filled in the United States (US), approximately 160 million patient lives. The data has broad representative coverage at both the geographic and payment levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sumatriptan/Naproxen combination | Sumatriptan and Naproxen Sodium |
| DRUG | other oral triptans | almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2011-04-11
- Last updated
- 2017-05-30
- Results posted
- 2011-04-11
Source: ClinicalTrials.gov record NCT01332500. Inclusion in this directory is not an endorsement.